High Risk of Deep Vein Thrombosis in Patients with Non-small Cell Lung Cancer: A Cohort Study of 493 Patients

Tagalakis, Vicky; Levi, Dahlia; Agulnik, J.; Cohen, Victor; Kasymjanova, G.; Small, David

doi:10.1097/jto.0b013e31811ea275

Cited by 97 publications

(76 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LC is the most common cause of cancer-related death worldwide (Jemal et al, 2009). Patients with LC show a high prevalence of VTE as observed by different authors (Blom et al 2004, Tagalakis et al 2007and Chew et al 2007 being one of the most common tumors in series of patients with cancer-related VTE (Seddighzadeh et al 2007, White at al 2005and Paneesha et al 2010. The thrombotic risk in patients with LC is 20-fold higher than in the general population according to findings by Blom et al (2004).…”

Section: Introductionsupporting

confidence: 57%

Venous Thromboembolism in Cancer Patients: Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study

Font¹,

Campayo²,

Farrús³

et al. 2013

ACRT

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 57%

Venous Thromboembolism in Cancer Patients: Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study

Font¹,

Campayo²,

Farrús³

et al. 2013

ACRT

View full text Add to dashboard Cite

show abstract

“…Lung cancer is the most commonly identified malignancy in patients with VTE (5), with an incidence of 3-13.9% in patients with VTE and that of up to 3.8% in patients with pulmonary embolism (PE) (6)(7)(8)(9).…”

Section: Original Articlementioning

confidence: 99%

Pulmonary embolism concurrent with lung cancer and central emboli predict mortality in patients with lung cancer and pulmonary embolism

Cha¹,

Shin²,

Lim³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Patients with lung cancer commonly experience pulmonary embolism (PE). The aim of the present study was to examine the clinical features of patients with lung cancer and PE and to investigate prognostic factors in these patients. Methods: This retrospective study divided patients with lung cancer and PE into a group of patients with PE diagnosed concomitantly with lung cancer (concurrent group) and a group with PE detected after lung cancer (sequential group), compared the clinical characteristics of patients in the two groups, and investigated prognostic factors in these patients. =2.64, 95% confidence interval (CI): 1.57-4.43, P<0.001] and central PE (HR =1.46, 95% CI: 1.02-2.10, P=0.04) were independent predictors of mortality in patients with lung cancer and PE. Conclusions: PE concurrent with lung cancer is characterized by more severe PE and infrequent small cell carcinoma. PE concurrent with lung cancer and central emboli may be independent prognostic factors in patients with lung cancer and PE. cancers (4). Lung cancer is the most commonly identified malignancy in patients with VTE (5), with an incidence of 3-13.9% in patients with VTE and that of up to 3.8% in patients with pulmonary embolism (PE) (6-9).The mechanisms of VTE in cancer patients, although not completely established, appear to be multifactorial (6,7). The occurrence of VTE in lung cancer has a prognostic implication, in that the survival of lung cancer patients with PE was shorter than that of those without PE (10). However, most deaths in patients with lung cancer and PE or VTE have been attributed to lung cancer rather than thromboembolism (11). These findings suggest that VTE may be a marker of an advanced stage cancer or of a more biologically aggressive tumor (12). A previous study including small numbers of patients demonstrated that patients with lung cancer with concurrently diagnosed PE had poorer survival than those without PE (10). In another study, no difference in survival was found between patients with PE diagnosed at less than 3 months after the diagnosis of lung cancer and those with PE diagnosed at 3 months or more following lung cancer diagnosis (13). Therefore, it is unclear whether the timing of the presentation of PE in patients with lung cancer may influence patient prognosis.Several factors that may determine short-term prognosis in patients with PE, including pulmonary embolism severity index (PESI) score, cardiac biomarkers, right ventricular (RV) dilation, and central emboli, have been proposed (14). However, information regarding these PE-related prognostic factors in patients with lung cancer and PE is lacking. The aim of the present study was to examine the clinical features of patients with lung cancer patients and PE, to compare clinical characteristics of PE found concurrently at lung cancer diagnosis and PE developed sequentially after the diagnosis of lung cancer, and to investigate the PE-related predictors of mortality in patients with lung cancer patients and PE. Methods Study designThe pre...

show abstract

“…Patients with cancer account for 0.6-13.6% of cases of VTE (6)(7)(8). Multiple interacting mechanisms are thought to explain the increased incidence of thrombosis in patients with malignancies.…”

Section: Discussionmentioning

confidence: 99%

“…Mucins are thought to be a trigger of coagulation (14) and cause induction of disseminated thrombosis (2,15). Meanwhile, the clinical risk factors and candidate laboratory biomarkers predictive of cancer-associated VTE have recently been assessed (7,8,16,17). These factors were reported as tumor type, stage of disease, hospitalization, elevation of platelet, leukocyte counts and D-dimer.…”

mentioning

confidence: 99%

Four Cases of Trousseau's Syndrome Associated with Lung Adenocarcinoma

et al. 2012

View full text Add to dashboard Cite

Cancer patients are at high risk of venous thromboembolism (VTE), and the combination of these two conditions is well known as Trousseau's syndrome. Here we present four cases of Trousseau's syndrome associated with advanced lung adenocarcinoma. In addition to fibrinogen degradation products (FDP) and Ddimer, the levels of mucin-producing markers, such as KL-6, were elevated. There is a possibility that mucin production may be associated with cancer-related VTE.

show abstract

High Risk of Deep Vein Thrombosis in Patients with Non-small Cell Lung Cancer: A Cohort Study of 493 Patients

Abstract: Our results show a high incidence of DVT in NSCLC patients. Advanced stage and, to a lesser extent, male sex, are important predictors of DVT. Trials to evaluate the use of prophylactic anticoagulant treatments in patients with NSCLC should be conducted.

Cited by 97 publications

References 31 publications

Venous Thromboembolism in Cancer Patients: Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study

Venous Thromboembolism in Cancer Patients: Comparison of Lung Cancer Patients to Other Solid Tumor Patients in a Prospective Observational Study

Pulmonary embolism concurrent with lung cancer and central emboli predict mortality in patients with lung cancer and pulmonary embolism

Four Cases of Trousseau's Syndrome Associated with Lung Adenocarcinoma

Contact Info

Product

Resources

About